ClinicalTrials.gg
CompletedNCT03747224Updated Dec 24, 2025

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

A Phase 1 interventional study of ARO-ANG3 and sterile normal saline (0.9% NaCl) in Dyslipidemias, Familial Hypercholesterolemia and Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Arrowhead Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Dyslipidemias with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Dyslipidemias · Australia.

Enrollment
24th of 41
93 · median 281
Started
2019
the only one that year
Phase 1
7 of 41
2 open now
Registered
28th of 41
by date
Lead sponsor
4 of 41
Arrowhead Pharmaceuticals

Among the 41 studies in Dyslipidemias with a site in Australia, this one is the 24th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 1, and was the 28th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

3 of the 41 studies in Dyslipidemias with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Dyslipidemias with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.

03

Conditions studied

  • Dyslipidemias
  • Familial Hypercholesterolemia
  • Hypertriglyceridemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use
  • Willing to provide written and to comply with study requirements
  • On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
  • Normal (ECG) at Screening

Exclusion criteria

Exclusion Criteria:

  • health concerns
  • Regular use of alcohol within one month prior to Screening
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study
  • Recent use of illicit drugs
  • Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)

NOTE: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    ARO-ANG3

    Drug: ARO-ANG3

  • Placebo comparator
    Placebo

    Drug: sterile normal saline (0.9% NaCl)

Interventions

  • single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections

  • Drugsterile normal saline (0.9% NaCl)

    calculated volume to match active treatment

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment

    Time frame: Up to 113 (+/- 3 days) post-dose

Secondary outcomes

  1. Pharmacokinetics (PK) of ARO-ANG3: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Single dose phase: Up to 48 hours post-dose

  2. PK of ARO-ANG3: Time to Maximum Plasma Concentration (Tmax)

    Time frame: Single dose phase: Up to 48 hours post-dose

  3. PK of ARO-ANG3: Terminal Elimination Half-Life (t1/2)

    Time frame: Single dose phase: Up to 48 hours post-dose

  4. PK of ARO-ANG3: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)

    Time frame: Single dose phase: Up to 48 hours post-dose

  5. PK of ARO-ANG3: Area Under the Plasma Concentration Versus Time Curve From Zero to infinity (AUCinf)

    Time frame: Single dose phase: Up to 48 hours post-dose

  6. Reduction in Fasting Serum ANGPTL3 from Pre-Dose Baseline

    Time frame: Baseline, Up to Day 113 (+/- 3 days)

07

Study locations

6 sites
  • Research Site 2
    Camperdown, New South Wales 2050, Australia
  • Research Site 3
    Adelaide, South Australia 5000, Australia
  • Research Site 1
    Nedlands, 6009, Australia
  • Research Site 4
    Grafton, Auckland 1010, New Zealand
  • Research Site 5
    Papatoetoe, Aukland 2025, New Zealand
  • Research Site 6
    Christchurch, 8011, New Zealand
08

References and documents

Publications

  • Watts GF, Scott R, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Gaudet D, Goldberg IJ, Knowles JW, Leeper NJ, Hegele RA, Ballantyne CM. Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial. Nat Med. 2026 Apr;32(4):1432-1443. doi: 10.1038/s41591-026-04307-8. Epub 2026 Apr 7. PubMed 41946917 ↗
  • Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023 Sep;29(9):2216-2223. doi: 10.1038/s41591-023-02494-2. Epub 2023 Aug 25. PubMed 37626170 ↗
  • Ying Q, Chan DC, Watts GF. Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management. Curr Opin Lipidol. 2021 Jun 1;32(3):210-212. doi: 10.1097/MOL.0000000000000747. No abstract available. PubMed 33900278 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in May 2021, 28 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 28 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2018
First posted
Nov 20, 2018
StartActual
Jan 7, 2019
Primary completionActual
May 17, 2021
CompletionActual
May 17, 2021
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747224
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Jan 7, 2019
Primary completion
May 17, 2021
Completion
May 17, 2021
Last update
Dec 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zodasiran

Start the discussion